Showing 3541-3550 of 19355 results for "".
Alloimmune Neutropenia of the Fetus and Newborn
https://reachmd.com/programs/cme/alloimmune-neutropenia-of-the-fetus-and-newborn/13910/NAIN is rare and potentially life-threatening. What clues can increase your awareness and help you modify the clinical course of this disease?The Patient-Clinician Connection in Managing CKD-aP
https://reachmd.com/programs/cme/the-patient-clinician-connection-in-managing-ckd-ap/36302/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Treat-to-Target: Are We There Yet?
https://reachmd.com/programs/cme/treat-to-target-are-we-there-yet/51485/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Applying Evidence to Clinical Practice
https://reachmd.com/programs/cme/applying-evidence-to-clinical-practice/36183/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Let’s Rewind: Recognizing NAFLD/NASH in the Primary Care Clinic
https://reachmd.com/programs/cme/lets-rewind-recognizing-nafldnash-in-the-primary-care-clinic/16020/Are you thinking NAFLD? As emerging therapies become available, PCPs need to be prepared to accurately identify patients at risk for NAFLD or NASH.Switching Strategies: Switch or Stay—What’s Your Call?
https://reachmd.com/programs/cme/switching-strategies-switch-or-staywhats-your-call/51487/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
https://reachmd.com/programs/cme/gmg-patient-stratification-and-antibody-profiling-personalizing-the-disease-lens/39029/Examine how antibody testing and patient characteristics inform personalized care when managing generalized myasthenia gravis.From Monoamines to Neurocircuits: Our Evolving Understanding of Depression
https://reachmd.com/programs/medical-industry-feature/monoamines-neurocircuits-understanding-depression/29735/Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept ofEarly Approaches to RAS Targeting: Efficacy Signals and Known Limitations
https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Expert Consensus on Physical Therapy for Acute and Sub-Acute Low Back Pain
https://reachmd.com/programs/clinicians-roundtable/expert-consensus-on-physical-therapy-for-acute-and-sub-acute-low-back-pain/26729/What are some effective interventions for managing low back pain? That’s the exact question an expert consensus sought to answer; here are the results.